Arun Arora, MD
Psychiatry · Bellevue, WANPI 1033555925
Payments from drug & device makers
What this record shows
Merck accounts for 67.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $2,328 and has fallen 79.4% since, to $479 in 2025. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $116.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Eli Lilly$479
- AbbVie$154
- Johnson & Johnson$125
- Janssen Research & Development, LLC$60
- Bristol Myers Squibb$59
- plus $118 from 3 others
Across 692 payments — averaging $15,262 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5M
- Janssen Research & Development, LLC$2.1M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.3M
- AbbVie$928K
- Boehringer Ingelheim International GmbH$542K
- Boehringer Ingelheim$466K
- plus $237K from 3 others
What the payments were for
- Travel & lodging$1,77759%
- Food & beverage$1,24641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 16 | $2,029 |
| Eli Lilly | 2 | $479 |
| AbbVie | 1 | $154 |
| Johnson & Johnson | 1 | $125 |
| Janssen Research & Development, LLC | 1 | $60 |
| Bristol Myers Squibb | 1 | $59 |
| Eisai Inc. | 1 | $56 |
| Boehringer Ingelheim | 2 | $36 |
| UCB SA | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,022 in reported general payments places this provider in the 90th percentile of 576 psychiatry providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Bellevue
- Aishwarya PrasadBellevue$7K
- Maryann BolteBellevue$4K
- Deborah HaynesBellevue$2K
- Arifulla KhanBellevue$1K
- Jeffrey HansenVancouver$2.8M
- Chester RobachinskiSeattle$1.1M
- Larry BornsteinEverett$663K
- Matthew BogoyasYakima$500K
- Pablo ProanoSeattle$112K
- David DunnerMercer Island$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.